Heat-inactivation of the BRS removed bactericidal activity. For all three isolates, 1/4 diluted human serum gave reduced or no bactericidal activity which appears to be a prozone effect ( Lieberman et al., 1988 and Zollinger and Mandrell, 1983). Similar results were obtained when the assay was repeated with BRS from Pel-Freez ( Fig. A.1). The findings indicate that

the amount of BRS used in serum bactericidal assay is critical and that the amount of BRS needed for killing is dependent on the target bacterial isolate. To verify that the observations made were not specific to the pooled Malawian serum used, we repeated the assay using two sera from 2 healthy individuals (1 European Talazoparib manufacturer and 1 Asian) as the antibody source (donor 1 and

Oligomycin A 2). The bactericidal activity of the three sera against the three Salmonella isolates was similar across the three BRS percentages tested ( Fig. A.2 and Fig. A.3). One method to detect functional antibodies in vaccinated or non-vaccinated human individuals by SBA is to use fresh undiluted human sera as both antibody and complement source. One advantage is that it is the most physiological and closest to ‘real-life’ scenario of bacteria in the bloodstream during invasive disease. However, sera from vaccinated individuals are often limited in quantity and are not necessarily handled to preserve complement integrity. Whole serum SBA does not permit the determination of a bactericidal titer, the minimum dilution of serum that can kill bacteria. Here, we examined the serum bactericidal activity of diluted fresh human serum against S. Typhimurium D23580, S. Typhimurium LT2 and S. Paratyphi A CVD1901. Our findings indicate that endogenous complement why in diluted

human sera can be limiting in a SBA against Salmonella. A 1/4 dilution of the human sera removed the bactericidal activity against S. Typhimurium D23580. This is consistent with our previous data where 10% human serum (a 1/10 dilution) was insufficient to effect bactericidal activity against S. Typhimurium D23580 ( MacLennan et al., 2008). Therefore, an exogenous source of complement is required when diluted human sera are used. Furthermore, if testing the efficacy of antibody to Salmonella generated in mice, SBA require an exogenous source of complement. This is because there is an absence of bactericidal activity in mouse sera due to impaired complement function ( Siggins et al., 2011). As most human sera contain naturally-acquired anti-Salmonella antibody, it is difficult to obtain human sera lacking anti-Salmonella antibody to use as an exogenous source of complement for SBA. Readily available BRS has been commonly used as the source of complement in SBA.